IRVINE, California,
July 10, 2017 /PRNewswire/
-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a pharmaceutical
company focusing on the development of ear, nose, and throat (ENT)
products, today announced that Jon
Kuwahara has joined the company as Senior Vice President of
Finance and Administration. He succeeds Christine G. Ocampo who will continue to be
engaged with the company as a consultant into 2018.
"We are fortunate to have Jon join the company at this
transformational time," said Gregory J.
Flesher, President and Chief Executive Officer of Novus
Therapeutics, Inc. "He is a seasoned finance executive with
extensive industry experience in both private and public
pharmaceutical companies. I welcome Jon and look forward to
working closely with him as we continue to build our company.
I also want to thank Christine for her extraordinary contributions
over the years. Christine has been instrumental in the
building of the organization and our recent transformation into a
public company. I wish her well in her future endeavors."
About Jon Kuwahara
Mr. Kuwahara has over 25 years of finance and operations
experience, primarily within the pharmaceutical industry.
Prior to joining Novus Therapeutics, Mr. Kuwahara served as Vice
President of Finance at Espero Pharmaceuticals, a private
pharmaceutical company focused on the development and
commercialization of cardiovascular products. Prior to
Espero, Mr. Kuwahara served in multiple roles, most recently as
Corporate Controller at Avanir Pharmaceuticals, a public
pharmaceutical company focused on the development and
commercialization of central nervous system products (acquired by
Otsuka Pharmaceuticals). Prior to Avanir, Mr. Kuwahara served
as Assistant Corporate Controller at Questcor Pharmaceuticals, a
public specialty pharmaceutical company (acquired by Mallinckrodt
Pharmaceuticals). Mr. Kuwahara is a member of the Board of
Directors, and Chairman of the Audit Committee, for Emmaus Life
Sciences, Inc., a biopharmaceutical company focused on rare and
orphan diseases. Mr. Kuwahara holds a B.B.A. with emphasis in
accounting from the University of
Hawaii and is a certified public accountant in California and Hawaii.
NASDAQ Inducement Grant Notice
Novus also announced the grant of an inducement award to Mr.
Kuwahara pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
In connection with his commencement of employment, Mr.
Kuwahara will be granted an inducement award consisting of a stock
option to purchase 35,000 shares of Novus common stock. The
stock option will vest over a period of four years, with 25%
vesting on the first anniversary of the grant date and the balance
vesting quarterly over the remaining three years. This award
will be granted on July 10, 2017,
which is the commencement of his employment with Novus, and the
stock option will have an exercise price equal to the closing price
of Novus's common stock on the date of grant. The award was
granted as an inducement material to Mr. Kuwahara's employment
pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
About Novus Therapeutics
Novus Therapeutics is a pharmaceutical company focusing on the
acquisition, development, and commercialization of ear, nose, and
throat (ENT) products. The company has two technologies, each
of which has the potential to be developed for multiple ENT
indications. The company's lead product is a
nasally-administered, combination drug product (OP-02) intended to
address the underlying cause of otitis media and Eustachian tube
dysfunction (OM/ETD), conditions that affect more than 700 million
people around the world every year. Otitis media is one of
the most common diseases seen by pediatricians and the most
frequent reason children consume antibiotics or undergo
surgery. The company also has a foam-based drug delivery
technology platform (OP-01) that can be used to deliver drugs into
the ear, nose, and sinus cavities. The company is currently
developing a foam-based combination drug-product delivered to the
external ear canal that is an improved treatment option for acute
otitis externa ("swimmers ear"). For more information on the
company, please visit novustherapeutics.com.
Investor Contacts
The Trout Group
Gita Ogawa
Tel: (646) 378-2949
gogawa@troutgroup.com
Novus Therapeutics, Inc.
Investor Relations
Tel: (949) 238-8090
investors@novustherapeutics.com
Logo -
http://mma.prnewswire.com/media/510083/NovusLogo_Color2_Logo.jpg